Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gram-negative bacterial cell envelope is a sophisticated multi-layered structure comprising an outer membrane (OM) and an inner cytoplasmic membrane (CM) (Source: Nature Reviews Microbiology, 2015). The OM is uniquely characterized by the presence of lipopolysaccharide (LPS), a glycolipid that serves as a potent endotoxin and a formidable permeability barrier against hydrophobic molecules and many antibiotics (Source: NIH, 2022). LPS is composed of three distinct regions: Lipid A, which anchors the molecule to the membrane; a core oligosaccharide; and an O-antigen polysaccharide chain. The cytoplasmic membrane is a phospholipid bilayer essential for maintaining the cell's electrochemical gradient, energy production, and selective transport of solutes. Therapeutic agents like polymyxins target this system by initially binding to the negatively charged phosphate groups of LPS, displacing stabilizing divalent cations (Mg2+ and Ca2+) and destabilizing the OM (Source: StatPearls, 2023). This allows the drug to penetrate the periplasm and insert into the CM, where it forms pores or disrupts the bilayer integrity, causing the leakage of vital intracellular contents and rapid cell death (Source: PubMed, 2019). While highly effective against multidrug-resistant pathogens, drugs targeting these membranes often face challenges due to potential toxicity in human cells and the emergence of resistance mechanisms such as LPS modification.
Disruption of the outer membrane through competitive displacement of divalent cations from lipopolysaccharide (LPS), followed by insertion into and permeabilization of the cytoplasmic membrane, leading to loss of membrane potential and leakage of intracellular contents.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane lipopolysaccharide and cytoplasmic membrane.